Category: Advances in Bioanalytics and Biomarkers
The highly dynamic post-transcriptional modification of RNA is involved in many regulatory cellular processes and the enzymes that control these changes represent an untapped set of drug targets. While it is possible to monitor RNA modifications indirectly using antibodies and various sequencing approaches, only mass spectrometry can give direct, quantifiable evidence of what chemical changes are occurring.
At STORM Therapeutics Ltd we have established a mass spectrometry platform that precisely quantifies over 70 different nucleosides and we have also placed some of these chemical changes into their sequence context. It is envisaged that using these technologies, we will be able to gain a more complete understanding of the in vivo function of RNA modifications.
Alan Hendrick– Senior Scientist, Storm Therapeutics, Cambridge, England, United Kingdom
Cambridge, England, United Kingdom
Alan Hendrick has been a senior scientist in the Mass Spectrometry and Assay Sciences Departments at Storm Therapeutics Ltd since January 2016. Prior to that he spent over fifteen years working in the in-vitro Pharmacology group at the Cambridge, UK site of Takeda Pharmaceuticals Ltd. He holds a BSc and PhD in Biochemistry from University College, Cork, Ireland.